Ashvin Shah, MD
Sleep Medicine · Yuma, AZNPI 1013015270
Payments from drug & device makers
Across 277 payments — averaging $313.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$38K
- Sanofi US Services Inc.$25K
- AstraZeneca$20K
- Jazz Pharmaceuticals Inc.$999
- Harmony Biosciences LLC$476
- Boehringer Ingelheim$290
- plus $2K from 31 others
What the payments were for
- Food & beverage$5,70492%
- Education$4718%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 38 | $37,559 |
| Sanofi US Services Inc. | 2 | $25,098 |
| AstraZeneca | 60 | $20,071 |
| Jazz Pharmaceuticals Inc. | 30 | $999 |
| Harmony Biosciences LLC | 14 | $476 |
| Boehringer Ingelheim | 13 | $290 |
| Genentech USA, Inc. | 10 | $232 |
| Regeneron Healthcare Solutions, Inc. | 11 | $230 |
| Philips North America LLC | 14 | $218 |
| Mylan Specialty L.p. | 11 | $209 |
| Electromed, Inc. | 13 | $174 |
| Sanofi | 8 | $164 |
| Grifols USA, LLC | 3 | $106 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Amgen | 4 | $93 |
| Astellas Pharma US Inc | 2 | $92 |
| Actelion Pharmaceuticals US, Inc. | 3 | $92 |
| Verona Pharma, Inc. | 3 | $86 |
| Eisai Inc. | 5 | $83 |
| Axsome Therapeutics, Inc. | 3 | $73 |
| Idorsia Pharmaceuticals US Inc | 3 | $58 |
| Advanced Respiratory, Inc | 2 | $53 |
| Fisher & Paykel Healthcare Inc | 2 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $44 |
| Sunovion Pharmaceuticals Inc. | 5 | $42 |
| Baxter Healthcare | 2 | $37 |
| Viatris Specialty LLC | 2 | $32 |
| AbbVie(2 entities) | 2 | $30 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $27 |
| Aerin Medical Inc. | 1 | $24 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $16 |
| Merck | 1 | $16 |
| Insmed, Inc. | 1 | $16 |
| CSL Behring | 1 | $14 |
| Olympus America Inc. | 1 | $12 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$86,937 in reported general payments places this provider in the 85th percentile of 47 sleep medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 12 | $160,447 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 120 | $132,942 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $20,037 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 12 | $5,377 |
| Wixela InhubFluticasone Propion/Salmeterol | 12 | $4,383 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 62 | $3,055 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $3,038 |
| Ventolin HfaAlbuterol Sulfate | 11 | $1,504 |
| Montelukast Sodium | 33 | $508 |
| Gabapentin | 28 | $425 |
| Azithromycin | 17 | $242 |
| Zolpidem Tartrate | 17 | $173 |
| Methylprednisolone | 25 | $149 |
| Eszopiclone | 12 | $84 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev | $290 | $160,44712 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $37,559 | $152,980136 claims |
| AstraZenecaBevespi Aerosphere, Symbicort | $20,071 | $8,41523 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 47 sleep medicine providers in Arizona.
Other sleep medicine in Yuma
- Chad RuoffScottsdale$1M
- Ruchir PatelScottsdale$581K
- Saif MashaqiTuscon$438K
- Joyce Lee-IannottiPhoenix$246K
- Sairam ParthasarathyTucson$194K
- Daniel CombsTucson$64K
- Jose de OcampoScottsdale$46K
- Jyotsna SahniTucson$38K
- Aynur OkcayTucson$14K
- Mohammad KhanChandler$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.